ARDS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARDS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Aridis Pharmaceuticals's book value per share for the quarter that ended in Sep. 2023 was $-0.27.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
Aridis Pharmaceuticals's current price is $0.0002. Its book value per share for the quarter that ended in Sep. 2023 was $-0.27. Hence, today's PB Ratio of Aridis Pharmaceuticals is .
The historical data trend for Aridis Pharmaceuticals's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aridis Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||
Book Value per Share | Get a 7-Day Free Trial | 3.25 | 0.41 | -0.86 | -0.74 | -0.90 |
Aridis Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Book Value per Share | Get a 7-Day Free Trial | -2.02 | -0.90 | -0.77 | -0.41 | -0.27 |
For the Biotechnology subindustry, Aridis Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aridis Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Aridis Pharmaceuticals's PB Ratio falls into.
Aridis Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (-24.23 | - | 0.00) | / | 27.03 | |
= | -0.90 |
Aridis Pharmaceuticals's Book Value Per Share for the quarter that ended in Sep. 2023 is calculated as:
Book Value Per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (-11.80 | - | 0.00) | / | 44.57 | |
= | -0.26 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Aridis Pharmaceuticals (OTCPK:ARDS) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Thank you for viewing the detailed overview of Aridis Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Vu Truong | director, 10 percent owner, officer: CEO, CSO, Director | 5941 OPTICAL CT., SAN JOSE CA 95138 |
Eric Patzer | director, 10 percent owner | 5941 OPTICAL CT., SAN JOSE CA 95138 |
Fibrosis Foundation Cystic | 10 percent owner | 4550 MONTGOMERY STREET, SUITE 1100N, BETHESDA MD 20814 |
Hasan Jafri | officer: Chief Medical Officer | 5941 OPTICAL COURT, SAN JOSE CA 95138 |
John F Hamilton | director | 1360 O'BRIEN DR, MENLO PARK CA 94025 |
Michael Adrian Nazak | officer: Chief Financial Officer | 5941 OPTICAL COURT, SAN JOSE CA 95138 |
Susan Richards Windham-bannister | director | 78 BLANCHARD ROAD, BURLINGTON MA 01803 |
Isaac Blech | director | C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
Fred Kurland | officer: Chief Financial Officer | C/O GENITOPE CORP, 525 PENOBSCOT DRIVE, REDWOOD CITY CA 94063 |
Wolfgang Dummer | officer: Chief Medical Officer | 5491 OPTICAL CT., SAN JOSE CA 95138 |
Robert R Ruffolo | director | |
Shawn Lu | director | C/O CANTEX PHARMACEUTICALS, INC., 1792 BELL TOWER LANE, WESTON FL 33326 |
Robert K. Coughlin | director | 5941 OPTICAL CT., SAN JOSE CA 95138 |
Craig S Gibbs | director | C/O FORTY SEVEN, INC., 1490 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025 |
From GuruFocus
By PRNewswire PRNewswire • 08-16-2022
By Marketwired • 08-02-2023
By GuruFocus Research • 02-12-2024
By ACCESSWIRE • 06-30-2023
By Value_Insider Value_Insider • 12-05-2022
By PRNewswire PRNewswire • 07-05-2022
By Value_Insider Value_Insider • 12-12-2022
By Marketwired • 07-12-2023
By Marketwired • 06-24-2024
By Value_Insider Value_Insider • 11-30-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.